TITLE:
Prognostic Value of the Matrix Metalloproteinase-9 and Its Relation to Clinicopathological Features in Women with Invasive Breast Cancer
AUTHORS:
Asmaa Mahmoud Fouad, Ahmed Moustafa Elzawawy, Sohair Elsayed Abdelmohsen, Noha Noufal
KEYWORDS:
Prognosis, Ductal Carcinoma, Matrix Metalloproteinase-9
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.7,
July
23,
2020
ABSTRACT: Background: Invasive breast cancer is the most common type of
malignancy in women worldwide. Matrix Metalloproteinase-9 is a member of degrading enzymes required for tumor metastasis. Aim: To assess the prognostic significance of the Matrix Metalloproteinase-9 expression in invasive breast cancer and
its association with the clinicopathological features. Patients and Methods: Cross-sectional study was conducted at the Oncology and Nuclear Therapy Unit,
Suez Canal University Hospital. The study involved 33 females that were
registered between January 1st, 2008 and December, 31st,
2012. The eligible participants had a confirmed non-metastatic invasive ductal
carcinoma, underwent surgery that their paraffin blocks containing tumor were
available. The participants’ tissue specimens were immune stained for Matrix
Metalloproteinase-9 expression
level in the hospital pathology lab. Survival analysis and correlation models
were conducted to explore the association between Matrix Metalloproteinase-9 expression level with clinicopathological
parameters and survival. Results: The mean age of participants was 51.2 ±
9.9 years. The mortality rate was 18.2%. The mean Matrix Metalloproteinase-9 expression was 5.42 (±3.37); 57.6% showed
high expression level. There was no significant correlation with clinicopathological
features. Nottingham Prognostic Index was a significant predictor of mortality.
Overall survival and disease-free survival were insignificantly different among
cases with low and high MMP-9 expression. Conclusion: Tissue Matrix
Metalloproteinase-9 expression
level does not play a significant role in disease progression. However,
Nottingham Prognosis Index is a significant predictor of mortality among
studied breast cancer cases.